ClinicalTrials.gg
CompletedNCT01574703CATSUpdated Dec 29, 2016Results posted

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

A Phase 4 interventional study of placebo and varenicline tartrate in Smoking Cessation, sponsored by Pfizer. Completed at 134 sites in 16 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-29.

Sponsored by Pfizer · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,595
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
2nd of 110
4,595 · median 209
Started
2012
with 5 others
Phase 4
47 of 110
3 open now
Registered
66th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 2nd largest by enrollment, is one of 6 that started in 2012, is one of 47 in phase 4, and was the 66th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.

Read the detailed description

This study is an extension protocol for study A3051123. No treatment is provided during this study. This study is to monitor for cardiovascular events 28 weeks after completion of A3051123. This study is an extension protocol for study A3051123. No treatment is provided during this study. This study is to monitor for cardiovascular events 28 weeks after completion of A3051123.

03

Conditions studied

  • Smoking Cessation

Keywords

  • smoking cessation
  • psychiatric disease
  • cardiovascular events
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be eligible if they were randomized to study A3051123.

Exclusion criteria

Exclusion Criteria:

  • Participation in study A3051123 ceased (ie, withdrew consent, lost to follow-up, etc) prior to final visit of study A3051123.
05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
4,595 participants (actual)

Study arms

  • Experimental
    placebo

    Drug: placebo

  • Experimental
    varenicline

    Drug: varenicline tartrate

  • Experimental
    bupropion

    Drug: bupropion hydrochloride

  • Experimental
    Nicotine Replacement Therapy Patch

    Drug: Nicotine Replacement Therapy Patch

Interventions

  • Drugplacebo

    All dosing to have taken place per study A3051123

  • All dosing to have taken place per study A3051123

    Also known as: Chantix; Champix

  • All dosing to have taken place per study A3051123

    Also known as: Zyban

  • DrugNicotine Replacement Therapy Patch

    All dosing to have taken place per study A3051123

    Also known as: NRT

06

What researchers measure

Primary outcomes

  1. Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.

    This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo.

    Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).

Secondary outcomes

  1. Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.

    This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio.

    Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days.

  2. Time to MACE Until the End of Study NCT01574703.

    This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio.

    Time frame: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).

  3. Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.

    This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug).

    Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).

  4. Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.

    This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.

    Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).

  5. Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.

    This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up.

    Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.

  6. Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.

    This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.

    Time frame: Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.

  7. Incidence of MACE Assessed Until End of Study NCT01574703.

    This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study.

    Time frame: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).

  8. Incidence of MACE+ Assessed Until End of Study NCT01574703.

    This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.

    Time frame: Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).

07

Results

Posted Dec 29, 2016

Participant flow

Of the 6293 participants who completed the parent study NCT01456936 as per protocol, a total of 4595 participants enrolled into this study NCT01574703 from 132 centers in 16 countries.

Participant flow — Overall Study
MilestoneVareniclineBupropionNicotine Replacement Therapy (NRT) PatchPlacebo
Started1192116611161121
Completed1067105410111007
Not completed125112105114
Withdrew: Adverse event0211
Withdrew: Protocol violation0001
Withdrew: Unspecified reason27152016
Withdrew: Withdrawal by subject53523661
Withdrew: Met withdrawal criteria0110
Withdrew: Lost to follow-up43414635
Withdrew: Death2110

Outcome measures

PrimaryTime to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.

This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug). The measure type mentioned in the outcome data table is Hazard Ratio relative to Placebo.

Time frame:
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Reported as:
Number · Unitless
Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
UnitlessVareniclineBupropionNRT PatchPlacebo
Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.0.29 (0.05 to 1.68)0.50 (0.10 to 2.50)0.29 (0.05 to 1.70)NA (NA to NA)
Statistical analysis
  • Varenicline vs Bupropion vs NRT Patch vs Placebo · Log Rank · p = 0.37 (P-value for the treatment effect from the Log-Rank test stratified by Cohort.)
SecondaryTime to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.

This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up. The measure type mentioned in the outcome data table is Hazard Ratio.

Time frame:
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days.
Reported as:
Number · Unitless
Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
UnitlessVareniclineBupropionNRT PatchPlacebo
Time to MACE up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.0.29 (0.05 to 1.70)0.51 (0.10 to 2.51)0.50 (0.10 to 2.48)NA (NA to NA)
Statistical analysis
  • Varenicline vs Bupropion vs NRT Patch vs Placebo · Log Rank · p = 0.53 (P-value for the treatment effect from the Log-Rank test stratified by Cohort.)
SecondaryTime to MACE Until the End of Study NCT01574703.

This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study. The measure type mentioned in the outcome data table is Hazard Ratio.

Time frame:
Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Reported as:
Number · Unitless
Time to MACE Until the End of Study NCT01574703.
UnitlessVareniclineBupropionNRT PatchPlacebo
Time to MACE Until the End of Study NCT01574703.0.39 (0.12 to 1.27)1.09 (0.42 to 2.83)0.75 (0.26 to 2.13)NA (NA to NA)
Statistical analysis
  • Varenicline vs Bupropion vs NRT Patch vs Placebo · Log Rank · p = 0.34 (P-value for the treatment effect from the Log-Rank test stratified by Cohort.)
SecondaryIncidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.

This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug).

Time frame:
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Reported as:
Number · percentage of participants
Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
percentage of participantsVareniclineBupropionNRT PatchPlacebo
Incidence of MACE Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.0.050.100.050.20
Statistical analysis
  • Varenicline vs Bupropion · Regression, Logistic · p = 0.8375 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.49 · 95% CI -5.22 to 4.23
  • Varenicline vs NRT Patch · Regression, Logistic · p = 0.9780 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.07 · 95% CI -5.20 to 5.05
  • Varenicline vs Placebo · Regression, Logistic · p = 0.6142 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -1.13 · 95% CI -5.54 to 3.27
  • Bupropion vs NRT Patch · Regression, Logistic · p = 0.8602 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): 0.42 · 95% CI -4.28 to 5.13
  • Bupropion vs Placebo · Regression, Logistic · p = 0.7217 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.64 · 95% CI -4.15 to 2.88
  • NRT Patch vs Placebo · Regression, Logistic · p = 0.6322 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -1.06 · 95% CI -5.41 to 3.28
SecondaryIncidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.

This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening peripheral vascular disease (PVD) requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.

Time frame:
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).
Reported as:
Number · percentage of participants
Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.
percentage of participantsVareniclineBupropionNRT PatchPlacebo
Incidence of MACE + Assessed During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936.0.250.200.100.25
Statistical analysis
  • Varenicline vs Bupropion · Regression, Logistic · p = 0.9687 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.07 · 95% CI -3.48 to 3.34
  • Varenicline vs NRT Patch · Regression, Logistic · p = 0.7905 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): 0.56 · 95% CI -3.58 to 4.70
  • Varenicline vs Placebo · Regression, Logistic · p = 0.8962 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.21 · 95% CI -3.36 to 2.94
  • Bupropion vs NRT Patch · Regression, Logistic · p = 0.7767 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): 0.63 · 95% CI -3.72 to 4.98
  • Bupropion vs Placebo · Regression, Logistic · p = 0.9260 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.14 · 95% CI -3.13 to 2.85
  • NRT Patch vs Placebo · Regression, Logistic · p = 0.7113 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.77 · 95% CI -4.85 to 3.31
SecondaryIncidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.

This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated during the treatment phase (up to date of last dose of study drug) plus 30 days follow-up.

Time frame:
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
Reported as:
Number · percentage of participants
Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
percentage of participantsVareniclineBupropionNRT PatchPlacebo
Incidence of MACE Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.0.050.100.100.20
Statistical analysis
  • Varenicline vs Bupropion · Regression, Logistic · p = 0.8117 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.57 · 95% CI -5.27 to 4.13
  • Varenicline vs NRT Patch · Regression, Logistic · p = 0.7303 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.78 · 95% CI -5.21 to 3.65
  • Varenicline vs Placebo · Regression, Logistic · p = 0.5946 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -1.20 · 95% CI -5.60 to 3.21
  • Bupropion vs NRT Patch · Regression, Logistic · p = 0.9200 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.21 · 95% CI -4.27 to 3.85
  • Bupropion vs Placebo · Regression, Logistic · p = 0.7236 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.62 · 95% CI -4.09 to 2.84
  • NRT Patch vs Placebo · Regression, Logistic · p = 0.8201 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.42 · 95% CI -4.01 to 3.17
SecondaryIncidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.

This is an adjudicated endpoint. MACE + is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.

Time frame:
Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks) plus 30 days follow-up.
Reported as:
Number · percentage of participants
Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.
percentage of participantsVareniclineBupropionNRT PatchPlacebo
Incidence of MACE+ Assessed up to Date of Last Dose of Study Drug Plus 30 Days Follow-up in Study NCT01456936.0.250.200.150.35
Statistical analysis
  • Varenicline vs Bupropion · Regression, Logistic · p = 0.8932 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.21 · 95% CI -3.22 to 2.81
  • Varenicline vs NRT Patch · Regression, Logistic · p = 0.8747 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.23 · 95% CI -3.09 to 2.63
  • Varenicline vs Placebo · Regression, Logistic · p = 0.6710 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.60 · 95% CI -3.35 to 2.15
  • Bupropion vs NRT Patch · Regression, Logistic · p = 0.9886 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.02 · 95% CI -3.32 to 3.27
  • Bupropion vs Placebo · Regression, Logistic · p = 0.7631 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.39 · 95% CI -2.92 to 2.14
  • NRT Patch vs Placebo · Regression, Logistic · p = 0.8022 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.37 · 95% CI -3.23 to 2.50
SecondaryIncidence of MACE Assessed Until End of Study NCT01574703.

This is an adjudicated endpoint. MACE is defined as a cardiovascular death, a non-fatal myocardial infarction or a non-fatal stroke evaluated until end of study.

Time frame:
Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Reported as:
Number · percentage of participants
Incidence of MACE Assessed Until End of Study NCT01574703.
percentage of participantsVareniclineBupropionNRT PatchPlacebo
Incidence of MACE Assessed Until End of Study NCT01574703.0.150.450.300.40
Statistical analysis
  • Varenicline vs Bupropion · Regression, Logistic · p = 0.6441 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.91 · 95% CI -4.78 to 2.96
  • Varenicline vs NRT Patch · Regression, Logistic · p = 0.7327 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.69 · 95% CI -4.63 to 3.26
  • Varenicline vs Placebo · Regression, Logistic · p = 0.6109 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.99 · 95% CI -4.80 to 2.82
  • Bupropion vs NRT Patch · Regression, Logistic · p = 0.8707 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): 0.22 · 95% CI -2.48 to 2.93
  • Bupropion vs Placebo · Regression, Logistic · p = 0.9531 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.08 · 95% CI -2.63 to 2.48
  • NRT Patch vs Placebo · Regression, Logistic · p = 0.8262 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.30 · 95% CI -2.99 to 2.39
SecondaryIncidence of MACE+ Assessed Until End of Study NCT01574703.

This is an adjudicated endpoint. MACE+ is defined as any MACE or a new onset or worsening PVD requiring intervention, a need for coronary revascularization, or hospitalization for unstable angina.

Time frame:
Baseline until end of study (end of study is defined as last visit in study NCT01574703 [up to Week 52], or in study NCT01456936 [up to 24 Weeks] for those participants not enrolled into study NCT01574703).
Reported as:
Number · percentage of participants
Incidence of MACE+ Assessed Until End of Study NCT01574703.
percentage of participantsVareniclineBupropionNRT PatchPlacebo
Incidence of MACE+ Assessed Until End of Study NCT01574703.0.500.750.490.60
Statistical analysis
  • Varenicline vs Bupropion · Regression, Logistic · p = 0.6105 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.59 · 95% CI -2.84 to 1.67
  • Varenicline vs NRT Patch · Regression, Logistic · p = 0.7895 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.32 · 95% CI -2.65 to 2.01
  • Varenicline vs Placebo · Regression, Logistic · p = 0.6804 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.48 · 95% CI -2.75 to 1.80
  • Bupropion vs NRT Patch · Regression, Logistic · p = 0.8127 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): 0.27 · 95% CI -1.95 to 2.49
  • Bupropion vs Placebo · Regression, Logistic · p = 0.9218 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): 0.11 · 95% CI -2.04 to 2.25
  • NRT Patch vs Placebo · Regression, Logistic · p = 0.8841 (P-values are for the risk differences of pairwise comparisons based on the logistic regression model with terms Baseline Cardiovascular Risk, treatment, cohort, region, and treatment by cohort interaction.) · Risk difference (rd): -0.16 · 95% CI -2.32 to 2.00

Adverse events

Collected over Adverse events were collected from Week 24 visit of study NCT01456936 until the end of study (i.e. Week 52 or date of discontinuation, as applicable).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—34/1,192 (2.9%)165/1,192 (13.8%)
Bupropion—39/1,166 (3.3%)160/1,166 (13.7%)
NRT Patch—43/1,116 (3.9%)116/1,116 (10.4%)
Placebo—41/1,121 (3.7%)143/1,121 (12.8%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventVareniclineBupropionNRT PatchPlacebo
Acute myocardial infarctionCardiac disorders0/11924/11662/11161/1121
PneumoniaInfections and infestations1/11920/11663/11160/1121
Atrial fibrillationCardiac disorders0/11920/11662/11161/1121
Gallbladder disorderHepatobiliary disorders0/11920/11662/11160/1121
AsthmaRespiratory, thoracic and mediastinal disorders1/11921/11662/11160/1121
Cardiac failure congestiveCardiac disorders0/11921/11660/11162/1121
AppendicitisInfections and infestations0/11921/11661/11162/1121
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/11921/11661/11162/1121
Major depressionPsychiatric disorders2/11921/11660/11162/1121
SchizophreniaPsychiatric disorders0/11922/11661/11162/1121
Most frequent other events
Most frequent other events
EventVareniclineBupropionNRT PatchPlacebo
NasopharyngitisInfections and infestations103/119278/116669/111681/1121
Upper respiratory tract infectionInfections and infestations63/119284/116648/111663/1121

Baseline characteristics

The term Baseline visit refers to the Baseline (Week 0) visit of the parent study NCT01456936. The safety population included all participants who received at least one dose of study drug in NCT01456936 parent study. The below Baseline characteristics (age, gender) are presented for all participants who entered study NCT01574703.

Age, Continuous
Age, Continuous(Years)VareniclineBupropionNRT PatchPlaceboTotal
Mean48.1 ± 12.247.7 ± 12.548.3 ± 11.947.5 ± 12.247.9 ± 12.2
Gender
Gender(Participants)VareniclineBupropionNRT PatchPlaceboTotal
Female6596486236212551
Male5335184935002044
08

Study locations

134 sites
  • Coastal Clinical Research, Inc.
    Mobile, Alabama 36608, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Synergy Clinical Research Center of Escondido
    Escondido, California 92025, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Omega Clinical Trials
    La Habra, California 90631, United States
  • Pacific Treatment and Research Center
    La Jolla, California 92037, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pharmacology Research Institute (PRI)
    Newport Beach, California 92660, United States
  • North County Clinical Research
    Oceanside, California 92056, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • University of Colorado Anschutz Medical Campus Behavioral Health and Wellness Program
    Aurora, Colorado 80045, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80209, United States
  • Comprehensive Psychiatric Care
    Norwich, Connecticut 06360, United States
  • Neuropsychiatric Research Center of Southwest Florida
    Fort Myers, Florida 33912, United States
  • Broward Research Group
    Hollywood, Florida 33024, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions
    Jacksonville, Florida 32256, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Ocala Psychiatric Associates
    Ocala, Florida 34474, United States
  • Clinical Neuroscience Solutions Inc.
    Orlando, Florida 32801, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Baber Research Group Incorporated
    Naperville, Illinois 60563, United States
  • Davis Clinic, Incorporated
    Indianapolis, Indiana 46250, United States
  • American Health Network of IN, LLC
    Indianapolis, Indiana 46254, United States
  • Goldpoint Clinical Research, LLC
    Indianapolis, Indiana 46260, United States
  • Vince & Associates Clinical Research, Inc.
    Overland Park, Kansas 66211, United States
  • Vince & Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
  • Vince and Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Central Kentucky Research Associates, Incorporated
    Lexington, Kentucky 40509, United States
  • Kentucky Research Group
    Louisville, Kentucky 40218, United States
  • The Center for Sexual Health
    Metairie, Louisiana 70002, United States
  • Maine Research Associates
    Auburn, Maine 04210, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Milford Emergency Associates, Incorporated
    Milford, Massachusetts 01757, United States
  • University of Minnesota - TC
    Minneapolis, Minnesota 55414, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Precise Research Centers
    Flowood, Mississippi 39232, United States
  • The Center for Pharmaceutical Research, PC
    Kansas City, Missouri 64114, United States
  • Mercy Health Research
    St. Louis, Missouri 63141, United States
  • CRI Worldwide, LLC
    Marlton, New Jersey 08053, United States
  • Global Medicinal Institutes, LLC; Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • SPRI Clinical Trails LLC
    Brooklyn, New York 11235, United States
  • Regional Clinical Research, Incorporated
    Endwell, New York 13760, United States
  • PMG Research of Raleigh, LLC
    Cary, North Carolina 27518, United States
  • Wake Internal Medicine Consultants, Inc
    Raleigh, North Carolina 27612, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Oregon Health and Science University
    Portland, Oregon 97239-3098, United States
  • Southeastern PA Medical Institute
    Broomall, Pennsylvania 19008, United States
  • Belmont Center for Comprehensive Treatment
    Philadelphia, Pennsylvania 19131, United States
  • Lincoln Research, LLC
    Lincoln, Rhode Island 02865, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Clinical Neuroscience Solutions,Inc
    Memphis, Tennessee 38119, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • James G. Kyser, MD
    Nashville, Tennessee 37203, United States
  • Future Search Clinical Trials
    Austin, Texas 78731, United States
  • InSite Clinical Research
    DeSoto, Texas 75115, United States
  • The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030-1439, United States
  • Clinical Research Associates of Tidewater, Inc
    Norfolk, Virginia 23507, United States
  • Centro de Investigacion Clinica WM
    Capital Federal, Buenos Aires C1440BRR, Argentina
  • Centro Medico Dra. De Salvo
    Buenos Aires, Capital Federal C1426ABP, Argentina
  • Monash Alfred Psychiatry Research Centre
    Melbourne, Victoria 3004, Australia
  • Hospital Sao Lucas da PUCRS - Uniao Brasileira de Educacao e Assistencia
    Porto Alegre, RS 90610-000, Brazil
  • Hospital e Maternidade Celso Pierro - Pontifícia Universidade Católica de Campinas - Campus II
    Campinas, São Paulo 13059-740, Brazil
  • Jaqueline Scholz Issa e Mario Issa de cardiologia Ltda
    Sao Paulo, 05017-000, Brazil
  • Mental Health Center "Prof. Dr. Ivan Temkov-Bourgas" Ltd.
    Bourgas, 8000, Bulgaria
  • MHAT "Dr. Hristo Stambolski" Ltd.
    Kazanlak, 6100, Bulgaria
  • NPH "Sv. Ivan Rilski"
    Novi Iskar, 1282, Bulgaria
  • UMHAT "Dr. Georgi Stranski" Ltd.
    Pleven, 5800, Bulgaria
  • UMHAT "Sveti Georgi" Ltd.
    Plovdiv, 4002, Bulgaria
  • SHATPPD - Ruse Ltd.
    Ruse, 7002, Bulgaria
  • Mental Health Center - Ruse Ltd.
    Ruse, 7004, Bulgaria
  • MHATNP "Sveti Naum" Ltd.
    Sofia, 1113, Bulgaria
  • MHATNP Sveti Naum SJsc.
    Sofia, 1113, Bulgaria
  • SHATPD - Troyan Ltd.
    Troyan, 5600, Bulgaria
  • Hamilton Medical Research Group
    Hamilton, Ontario L8M 1K7, Canada
  • Medical Research Associates
    Mississauga, Ontario L5M 4N4, Canada
  • University of Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3J 2C5, Canada
  • Centre for Addiction and Mental Health (CAMH)
    Toronto, Ontario M5S 2S1, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Hospital Regional de Talca, Unidad de Enfermedades Respiratorias
    Talca, Maule 3460001, Chile
  • Centro Respiratorio Integral (CENRESIN Ltda.)
    Quillota, Valparaiso, V Region 2260877, Chile
  • CCBR A/S
    Ballerup, 2750, Denmark
  • CCBR A/S
    Vejle, DK-7100, Denmark
  • Mehiläinen Leppävaara
    Espoo, 02600, Finland
  • Savon Psykiatripalvelu Oy
    Kuopio, 70110, Finland
  • Mehiläinen Nummela
    Nummela, 03100, Finland
  • Oulu Mentalcare Oy
    Oulu, 90100, Finland
  • Porin Lääkäritalo Oy
    Pori, 28100, Finland
  • PEL, Psykiatrian ErikoisLääkärit
    Turku, 20100, Finland
  • Universitaetsklinikum Freiburg
    Freiburg, Baden-wuerttemberg 79104, Germany
  • Ludwig Maximilians-Universitaet Muenchen
    Muenchen, Bayern 80336, Germany
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany

Showing the first 100 of 134 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018 May 1;178(5):622-631. doi: 10.1001/jamainternmed.2018.0397. PubMed 29630702 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2012
First posted
Apr 10, 2012
Start
May 2012
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Results first posted
Dec 29, 2016
Last update
Dec 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01574703
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 10, 2012
Start date
May 2012
Primary completion
Jul 2015
Completion
Jul 2015
Results posted
Dec 29, 2016
Last update
Dec 29, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Varenicline · Bupropion

Start the discussion